- Business
- MediPal Holdings Corporation MediPal Holdings Corporation (TSE: 7459), founded in 1898 and headquartered in Tokyo, Japan, operates as a holding company overseeing the wholesale distribution of pharmaceuticals, healthcare products, cosmetics, daily necessities, and animal health items across Japan through a network of over 300 bases from Hokkaido to Okinawa. Its core segments encompass the Prescription Pharmaceutical Wholesale Business, conducted via subsidiaries including MEDICEO Corporation, EVERLTH Co., Ltd., ATOL Co., Ltd., TOSHICHI Co., Ltd., SPLine Corporation, MM Corporation, ASTEC Co., Ltd., PharField Corporation, MEDIE Co., Ltd., PreMedica Inc., FloraDiscovery Inc., MIC Co., Ltd., Medipal Insurance Service, PRESUSCUBE Corporation, MEDISKET Corporation, and Kachidoki Yakuhin, which procures and delivers prescription drugs, medical equipment, materials, clinical diagnostic reagents, and related healthcare products to hospitals, clinics, and dispensing pharmacies; the Cosmetics, Daily Necessities and OTC Pharmaceutical Wholesale Business, led by PALTAC Corporation, supplying beauty, health, and over-the-counter products to drugstores, home centers, convenience stores, and supermarkets with services like in-store merchandising, product composition analysis, shelf allocation, inventory management, and handling of new or discontinued items; and the Animal Health Products and Food Processing Raw Materials Wholesale Business, managed by MP AGRO Co., Ltd. and MP Gokyo Food & Chemical Co., Ltd., distributing veterinary products to animal hospitals, farms, and cooperatives alongside raw materials and additives to food processors. Recent developments include the acquisition of PRESUSCUBE Corporation as a subsidiary in April 2023 with additional investment in July 2024 to enhance digital transformation support for insurance pharmacies via tools like BHI management analysis and PRESUS business systems, leveraging MEDIPAL's logistics and sales resources; full ownership of Toshichi Inc. in April 2023, PreMedica Inc. and FloraDiscovery Inc. in May 2024, and Sumitomo Pharma Food & Chemical Co., Ltd. (now MP Gokyo Food & Chemical) in March 2023; a global licensing and co-development agreement with JCR Pharmaceuticals in September 2025 for JR-479, expanding on prior ultra-rare disease collaborations including JR-471 and JR-446 since 2022; the launch of a group brand website and official social media accounts in January 2025; and active pursuit of mergers and acquisitions in 2025 to diversify amid shrinking drug margins, alongside the April 2025 merger of MVC Co., Ltd. into ATOL Co., Ltd.